Calcium antagonists and atherosclerosis.
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control; D002118:Calcium / Q000037:antagonists & inhibitors* / Q000502:physiology; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D004036:Diet, Atherogenic; D004164:Diphosphonates / Q000627:therapeutic use; D004549:Elastin / Q000378:metabolism; D012968:Etidronic Acid / Q000627:therapeutic use; D006801:Humans; D007811:Lanthanum / Q000627:therapeutic use; D008252:Macaca fascicularis; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000473:pathology / Q000503:physiopathology; D010879:Piperazines / Q000627:therapeutic use; D011817:Rabbits
D004164:Diphosphonates; D010879:Piperazines; C005185:trimazosin; C031876:azacycloheptane-2,2-diphosphonate; D007811:Lanthanum; C046515:2-iminopyrrolidone-5,5-diphosphonic acid; D003094:Collagen; D004549:Elastin; D002784:Cholesterol; D012968:Etidronic Acid; D002118:Calcium